- Home
- AKRO vs ACLX Comparison
AKRO vs ACLX Comparison
Compare AKRO & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- ACLX
- Stock Information
- Founded
- AKRO 2017
- ACLX 2015
- Country
- AKRO United States
- ACLX United States
- Employees
- AKRO N/A
- ACLX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- ACLX Health Care
- Exchange
- AKRO Nasdaq
- ACLX Nasdaq
- Market Cap
- AKRO 4.5B
- ACLX 4.4B
- IPO Year
- AKRO 2019
- ACLX 2022
- Fundamental
- Price
- AKRO $54.31
- ACLX $90.01
- Analyst Decision
- AKRO Buy
- ACLX Strong Buy
- Analyst Count
- AKRO 10
- ACLX 8
- Target Price
- AKRO $73.56
- ACLX $115.50
- AVG Volume (30 Days)
- AKRO 1.7M
- ACLX 427.8K
- Earning Date
- AKRO 11-07-2025
- ACLX 11-05-2025
- Dividend Yield
- AKRO N/A
- ACLX N/A
- EPS Growth
- AKRO N/A
- ACLX N/A
- EPS
- AKRO N/A
- ACLX N/A
- Revenue
- AKRO N/A
- ACLX $35,898,000.00
- Revenue This Year
- AKRO N/A
- ACLX N/A
- Revenue Next Year
- AKRO N/A
- ACLX $220.95
- P/E Ratio
- AKRO N/A
- ACLX N/A
- Revenue Growth
- AKRO N/A
- ACLX N/A
- 52 Week Low
- AKRO $21.34
- ACLX $47.86
- 52 Week High
- AKRO $58.40
- ACLX $100.34
- Technical
- Relative Strength Index (RSI)
- AKRO 68.45
- ACLX 57.21
- Support Level
- AKRO $53.90
- ACLX $85.00
- Resistance Level
- AKRO $54.37
- ACLX $91.68
- Average True Range (ATR)
- AKRO 0.20
- ACLX 4.14
- MACD
- AKRO -0.23
- ACLX -0.08
- Stochastic Oscillator
- AKRO 87.20
- ACLX 71.76
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.